Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Zafgen Inc. (obesity therapeutics) has raised $33mm through its Series C venture round. Atlas Venture and Third Rock Ventures led the financing and were joined by other current shareholders. The company will use the money to move ZGN433, its lead methionine aminopeptidase 2 inhibitor, into Phase II studies within the next year. The drug candidate is an alternative to bariatric surgery for severely obese patients.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?